Park Place Capital Corp Decreases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Park Place Capital Corp cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 55.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 209 shares of the medical research company’s stock after selling 264 shares during the quarter. Park Place Capital Corp’s holdings in Charles River Laboratories International were worth $39,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the period. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $32,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $56,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of analyst reports. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price target for the company. Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and an average target price of $204.38.

Charles River Laboratories International Stock Down 0.9 %

NYSE CRL opened at $166.75 on Friday. The company has a market capitalization of $8.53 billion, a P/E ratio of 20.87, a P/E/G ratio of 5.97 and a beta of 1.38. The stock has a 50 day moving average price of $187.21 and a 200-day moving average price of $197.51. Charles River Laboratories International, Inc. has a one year low of $160.85 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the company earned $2.72 earnings per share. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).